NL
MRNA icon

Navalign LLC’s Moderna MRNA Stock Holding History

Navalign LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$295 – 345
2025
Q4 		$295 Buy
+10
New +$272 ﹤0.01% 478

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Navalign LLC's MRNA Position: Q1 2026 in Review

Navalign LLC sold out of Moderna (MRNA) in Q1 2026, closing a stake of 10 shares — an estimated $295 sold.

Navalign LLC first reported a position in MRNA in Q4 2025 and held it in 1 quarter. The position peaked at $295 in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Navalign LLC reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Navalign LLC sold 10 Moderna shares in Q1 2026, an estimated $295.
  • Navalign LLC first reported a position in Moderna in Q4 2025 and held it in 1 quarter.
  • Navalign LLC's Moderna position peaked at $295 in Q4 2025.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.